The European Medicines Agency (EMA) recently launched an investigation into Novo Nordisk's GLP-1 treatments, including Saxenda (ingredient: liraglutide), Ozempic (ingredient: semaglutide), and Wegovy (ingredient: semaglutide), after the Icelandic Medicines Agency reported two adverse events of suicidal or self-harming behavior in patients taking Saxenda and Ozempic
Getting this step wrong can undermine even the most well-designed study before it even begins
This study aims to explore this gap by utilizing data from the large community-based database, TriNetX, to investigate the association between GLP-1 RA use and the risk of psychiatric diseases, including major depression, anxiety and suicidal behaviour in patients with obesity
Step 4: Receive reimbursement from your health account
By having better control of blood sugar levels helps reduce the risk of complications of diabetes
The team includes approximately 40 undergraduate members from a variety of engineering disciplines